Understanding Barriers to Initiation and Adherence to Adjuvant Endocrine Therapy in Young Breast Cancer Survivors of Diverse Racial, Ethnic, and Socio-economic Backgrounds: The EMPOWER Study
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 17
- 试验地点
- 1
- 主要终点
- Decision-making around endocrine therapy in young women with HR+ breast cancer.
研究概览
简要总结
The overall goal of this study is to qualitatively explore how behavioral, cultural, psychosocial, and economic barriers and facilitators affect the decision to start and adhere to endocrine therapy (ET) among young breast cancer survivors of diverse racial, ethnic, and socio-economic backgrounds with hormone receptor positive (HR+) breast cancer
详细描述
A qualitative study that will use interviews to gain an in depth understanding of factors affecting the decision to start and adhere to endocrine therapy (ET) among young breast cancer survivors of diverse racial, ethnic, and socio-economic backgrounds with hormone receptor positive (HR+) breast cancer
研究设计
- 研究类型
- Observational
- 观察模型
- Other
- 时间视角
- Other
入排标准
- 年龄范围
- 18 Years 至 45 Years（Adult）
- 性别
- Female
- 接受健康志愿者
- 是
入选标准
- •Are Hispanic, Latina, Black, or identify as socio-economically disadvantaged (any racial/ethnic background) as measured by an item of financial distress answering that they are "having difficulty paying the bills no matter what they do" to a question about their current household financial situation.18, 19
- •report a history of Stage 1-3 breast cancer
- •reports HR+ breast cancer and confirm that they have had a discussion with their doctor about adjuvant ET; OR indicate that they are taking ET, even if they do not know their HR status, answer they are HR-, or do not recall having a discussion about ET)
- •not in active treatment (e.g., chemotherapy, radiation), with the exception of Herceptin
- •at least 3 months, but no more than 3 years out of completion of active treatment
- •no evidence of recurrent/metastatic disease
- •at least 18, but< 45 years of age at diagnosis of first invasive breast cancer
- •English or Spanish speaking
- •are willing to consent to the interview
排除标准
- •HR- breast cancer and indicate they are not taking ET
- •HR+ breast cancer but do not confirm discussion of ET or indicate they are taking ET
- •Stage 0 (DCIS) breast cancer
- •Recurrent or metastatic disease
- •Less than 3 months or more than 3 years post-active treatment
- •Less than 18 years old or ≥45 years old at diagnosis
结局指标
主要结局
Decision-making around endocrine therapy in young women with HR+ breast cancer.
时间窗: 3 months-3 years post active treatment
Open ended questions
次要结局
- Barriers and challenges to endocrine therapy adherence(3 months-3 years post active treatment)
- Menopausal symptoms(3 months-3 years post active treatment)
- Social support(3 months-3 years post active treatment)
- Health behaviors(3 months-3 years post active treatment)
- Endocrine therapy adherence intervention preferences(3 months-3 years post active treatment)
- Health literacy(3 months-3 years post active treatment)
研究者
Rachel Freedman, MD, MPH
Principal Investigator
Dana-Farber Cancer Institute